Date: 2016-11-22
Type of information: Production agreement
Compound:
Company: Autolus (UK) Cell and Gene Therapy Catapult (UK)
Therapeutic area:
Type agreement: production - manufacturing
Action mechanism:
Disease:
Details:
- • On November 22, 2016, Autolus and the Cell and Gene Therapy Catapult have signed an agreement for Autolus to become the first company to enter the CGT Catapult’s manufacturing centre in Stevenage. Autolus will occupy one of the first of six manufacturing modules set up to support commercial scale cell therapy manufacturing. Autolus’ initial activities for setting up and running GMP processes will also facilitate approval and licensure of the centre by the MHRA, which is expected in early 2018.
- The CGT Catapult manufacturing centre will enable firms to serve a global market from the UK. The independent modules in the centre have been designed to flex to an autologous, allogeneic or viral vector process and can be adapted to support to any cell or gene therapy company seeking to develop new market ready GMP processes.
Financial terms:
Latest news:
Is general: Yes
